Publication | Open Access

Novel design principle validated: Glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent

Medicinal ChemistryDiabetes ManagementNovel Design PrincipleBiochemistryNew Nanomolar InhibitorMedicineNatural SciencesDiabetesGlycobiologyPharmacological AgentGlycogen PhosphorylaseDrug DevelopmentPharmacologyDrug DiscoveryGlycosylation